Baron Health Care Fund retreated in the first quarter of 2025, underperforming its benchmark, the Russell 3000 Health Care ...

Bamlanivimab and etesevimab combination has been authorised under Emergency Use Authorisation in the US and select EU countries for the treatment of the disease.